Adult T-Cell Leukemia/Lymphoma.

Area of Science:

• Oncology
• Virology
• Hematology

Background:

• Adult T-cell leukemia/lymphoma (ATL) is a rare T-cell lymphoproliferative neoplasm linked to human T-lymphotropic virus 1 (HTLV-1).
• ATL presents with diverse clinical subtypes, including acute, lymphoma, chronic, and smoldering forms, significantly impacting patient prognosis.
• Aggressive ATL subtypes are associated with poor outcomes among non-Hodgkin lymphomas.

Purpose of the Study:

• To review the current understanding of Adult T-cell leukemia/lymphoma (ATL) pathogenesis and clinical manifestations.
• To summarize established and emerging therapeutic strategies for various ATL subtypes.
• To highlight the potential of novel agents and future directions in ATL treatment.

Main Methods:

• Literature review of studies on Adult T-cell leukemia/lymphoma (ATL).
• Analysis of clinical trial data and treatment outcomes for ATL.
• Synthesis of information on molecular drivers and therapeutic targets in ATL.

Main Results:

• Smoldering and lower-risk chronic ATL forms show some response to antiviral therapies.
• Aggressive ATL subtypes benefit from combination chemotherapy followed by allogeneic transplantation.
• Mogamulizumab and lenalidomide demonstrate promise in recent ATL treatment studies.

Conclusions:

• ATL management requires subtype-specific approaches, ranging from antiviral therapies to intensive chemotherapy and transplantation.
• Emerging treatments like mogamulizumab and lenalidomide offer new hope for ATL patients.
• Continued research into ATL's molecular landscape is crucial for expanding therapeutic options.